Investment Thesis
HaloZyme demonstrates strong 37.6% YoY revenue growth and exceptional free cash flow generation, but the 28.6% YoY decline in net income despite higher revenues indicates deteriorating earnings quality. The dangerously elevated 8.81x debt-to-equity ratio combined with an unsustainable 1.6% gross margin signals fundamental business model challenges and elevated financial risk.
Strengths
- Strong revenue growth of 37.6% YoY with $376.7M in sales
- Exceptional free cash flow generation of $176.3M with 46.8% FCF margin demonstrating strong cash conversion
- Robust liquidity and interest coverage with 2.76x current ratio and 40.9x interest coverage ratio
Risks
- Net income declined 28.6% YoY and EPS fell 25.4% despite strong revenue growth, indicating poor earnings quality and unsustainable business model
- Critically high debt-to-equity ratio of 8.81x ($1.9B debt vs. $219.6M equity) creates substantial financial leverage risk and limits operational flexibility
- Exceptionally low gross margin of 1.6% is unsustainable and suggests fundamental cost structure or competitive pressures that threaten long-term profitability
Key Metrics to Watch
- Gross margin trend and revenue composition drivers - unsustainable 1.6% margin must improve
- Debt-to-equity ratio and long-term debt levels - 8.81x leverage is dangerously high for declining profitability
- Operating cash flow sustainability and net income recovery - critical divergence between top-line growth and bottom-line performance must reverse
Financial Metrics
Revenue
376.7M
Net Income
150.0M
EPS (Diluted)
$1.22
Free Cash Flow
176.3M
Total Assets
2.7B
Cash
309.7M
Profitability Ratios
Gross Margin
1.6%
Operating Margin
49.0%
Net Margin
39.8%
ROE
68.3%
ROA
5.6%
FCF Margin
46.8%
Balance Sheet & Liquidity
Current Ratio
2.76x
Quick Ratio
2.33x
Debt/Equity
8.81x
Debt/Assets
91.8%
Interest Coverage
40.94x
Long-term Debt
1.9B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-12T07:12:11.263316 |
Data as of: 2026-03-31 |
Powered by Claude AI